Immunocore stock price, funding rounds, valuation and financials

Immunocore has raised $490 m in total funding. Immunocore annual revenue was £24.28 m in FY 2018

£24.3 M

Immunocore Revenue FY, 2018
Immunocore Gross profit (FY, 2018)-59.3 M
Immunocore Gross profit margin (FY, 2018), %(244.3%)
Immunocore Net income (FY, 2018)-71.6 M
Immunocore EBIT (FY, 2018)-93.5 M
Immunocore Cash, 31-Dec-2018124.4 M

Immunocore Funding

Summary Metrics

Immunocore's latest funding round in March 2020 was reported to be $170 m. In total, Immunocore has raised $490 m

Immunocore Capital Raised

Embed Graph

Immunocore Income Statement

Annual

GBPFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

2.0m6.4m14.3m17.3m14.6m24.3m

Revenue growth, %

212%

Cost of goods sold

83.6m

Gross profit

(59.3m)

Gross profit Margin, %

(244%)

Operating expense total

6.8m13.7m(2.9m)49.8m82.1m

Depreciation and amortization

6.4m

EBITDA

(4.4m)(7.3m)18.9m(51.7m)(63.4m)

EBITDA margin, %

(213%)(115%)132%(299%)(436%)

EBIT

(4.8m)(7.3m)17.2m(32.5m)(67.5m)(93.5m)

EBIT margin, %

(234%)(115%)120%(188%)(464%)(385%)

Interest expense

842.0k

Interest income

1.1m

Pre tax profit

(4.8m)(7.2m)18.0m(31.2m)(64.7m)(88.2m)

Income tax expense

1.1m1.6m(1.2m)8.1m15.8m(16.5m)

Net Income

(3.7m)(5.6m)16.8m(23.1m)(48.9m)(71.6m)

Immunocore Balance Sheet

Annual

GBPFY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

7.2m3.4m5.0m3.8m2.3m16.3m50.9m219.7m134.4m82.9m124.4m

Accounts Receivable

1.1m1.2m2.0m1.6m307.3k203.0k186.0k1.0m258.0k4.4m

Inventories

Current Assets

7.2m4.5m6.1m5.8m3.9m18.0m54.3m228.7m191.2m143.5m171.2m

PP&E

305.2k493.6k624.2k1.1m1.3m2.6m7.8m27.6m23.9m20.9m

Goodwill

257.9k207.0k90.0k

Total Assets

7.2m5.3m7.0m6.8m5.3m19.6m60.9m273.2m219.2m195.4m195.8m

Accounts Payable

491.0k574.0k1.3m1.6m566.6k825.0k3.6m3.1m8.0m6.4m

Short-term debt

Current Liabilities

491.0k574.0k1.3m1.6m8.4m18.6m22.6m21.8m29.8m49.6m

Long-term debt

18.9m

Non-Current Liabilities

8.1m44.4m36.4m22.3m29.9m89.6m

Total Debt

18.9m

Total Liabilities

491.0k574.0k1.3m1.6m16.6m63.0m59.0m44.1m59.7m139.2m

Common Stock

889.0985.01.3k1.6k1.8k1.9k2.0k

Retained Earnings

(22.2m)(27.8m)(11.0m)(61.1m)(110.0m)(175.2m)

Total Equity

7.2m4.8m6.4m5.6m3.7m3.0m(2.1m)214.3m175.1m135.7m56.6m

Debt to Equity Ratio

0.3 x

Debt to Assets Ratio

0.1 x

Financial Leverage

1 x1.1 x1.1 x1.2 x1.4 x6.5 x-28.9 x1.3 x1.3 x1.4 x3.5 x

Immunocore Cash Flow

Annual

GBPFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(3.7m)(5.6m)16.8m(23.1m)(48.9m)

Cash From Operating Activities

11.3m40.3m(22.4m)(36.9m)(60.9m)(16.6m)

Cash From Investing Activities

58.0m

Cash From Financing Activities

3.0m404.0k197.7m96.0k19.1m101.0k

Net Change in Cash

13.8m34.5m168.9m(7.4m)(51.5m)41.5m

Income Taxes Paid

1.1m1.6m12.3m

Immunocore Ratios

GBPY, 2018

Revenue/Employee

67.3k

Debt/Equity

0.3 x

Debt/Assets

0.1 x

Financial Leverage

3.5 x

Immunocore Employee Rating

3.451 votes
Culture & Values
3.3
Work/Life Balance
3.7
Senior Management
2.8
Salary & Benefits
2.9
Career Opportunities
2.9
Source